Superworth

BIO-TECHNE TECH

Biotechnology, Healthcare
$72.67
+0.01%
Market cap
$11.4B
PE
63.2×
10y median 62.0×
Forward PE
n/m
not a meaningful number
Price to sales
9.4×
EV/EBIT
45.0×
Revenue, 12 months
$1.2B
−0% on a year ago
Net margin
15.0%
Free cash flow yield
2.3%

BIO-TECHNE trades at 63.2× trailing earnings, near its ten-year median. Revenue was $1.2B over the last twelve months, down 0% on a year earlier with a 15% net margin.

Charts

Financials

Income statement for TECH, by quarter
Income statementQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
$276.9M+3%$272.6M+0%$303.4M+3%$306.1M+2%$289.5M+5%$297M+9%$316.2M+4%$317M+4%$286.6M−1%$295.9M−0%$311.4M−2%$321.2M+1%
Cost of revenue$91.7M+2%$96M+9%$98.8M+7%$102.8M+6%$106.4M+16%$103.1M+7%$101.6M+3%$118.2M+15%$98.4M−8%$104.6M+1%$103.1M+2%$109.8M−7%
Gross profit$185.2M+3%$176.6M−4%$204.6M+1%$203.3M−1%$183M−1%$193.9M+10%$214.6M+5%$198.8M−2%$188.1M+3%$191.3M−1%$208.3M−3%$211.4M+6%
R&D$24M+0%$22.9M+2%$25.8M+13%$24M+2%$23.9M−1%$25M+9%$24.6M−5%$26M+9%$24.2M+2%$23.1M−8%$23.5M−5%$23.9M−8%
SG&A$105.3M+6%$115.7M+24%$111.8M+13%$133.5M+54%$119.2M+13%$121.5M+5%$151.3M+35%$196.6M+47%$116.2M−3%$113.7M−6%$109.3M−28%$113.2M−42%
$55.9M−1%$38M−44%$67M−17%$45.8M−52%$40M−28%$47.4M+25%$38.7M−42%−$23.9M$47.7M+19%$54.5M+15%$75.5M+95%$74.3M
Interest expense$4.9M+29%$4.3M+84%$4M+193%$2.5M−32%$2.2M−56%$2.1M−50%$2M−50%$2.2M−13%$2.9M+35%$2.2M+1%$2.4M+20%$2.1M−3%
Pre-tax income$49.6M−52%$33.4M−50%$61.1M−24%$41.7M−53%$40.2M−19%$42.9M+28%$38.3M−37%−$22.9M$48M+20%$50.8M+18%$71.2M+86%$70.7M
−$1.4M$5.9M−64%$12M+21%$1.1M−92%$6.6M$8M+35%$15.7M+30%−$5.2M$9.8M+49%$12.8M+60%$20.2M+29%$16.1M
Net income$51M−43%$27.5M−45%$49.1M−30%$40.6M−46%$33.6M−34%$34.9M+27%$22.6M−54%−$17.7M$38.2M+14%$38M+9%$51M+126%$54.6M
$0.31−44%$0.17−45%$0.31−28%$0.25−47%$0.21−32%$0.22+29%$0.14−55%−$0.11$0.24+14%$0.24+9%$0.32+129%$0.35
161.9M−0%160.1M−1%160.5M−1%160.6M−1%161.1M−1%160.6M+0%158.9M−1%155.7M−3%156.4M−3%157M−2%157.4M−1%157.2M+1%

EPS, diluted: 16 periods, Q4 FY10 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: 12 periods, Q4 FY10 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
TECHBIO-TECHNE$11.4B63.2×62.0×n/m9.4×−0%15.0%
RGENRepligen$9.8B237×123×n/m12.4×+16%5.3%
HALOHalozyme Therapeutics$14.6B38.5×21.3×n/m8.8×+41%24.9%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×n/m4.4×+34%20.9%
KRYSKrystal Biotech$8.8B37.1×42.5×n/m19.9×+23%54.8%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
INCYIncyte$24.3B15.3×36.5×51.3×4.2×+27%27.7%
UTHRUnited Therapeutics$25.9B21.6×14.2×22.6×8.2×+2%41.6%
ONCBeOne Medicines$40.2B63.2×67.6×45.0×6.6×+34%10.7%
ADMAAdma Biologics$2.5B15.8×21.3×n/m4.8×+8%33.0%
Peer median$16.1B24.4×39.5×33.8×6.8×+25%26.3%

Investors who own it

Investors we follow who held BIO-TECHNE at the end of Jun 30, 2026, from their 13F filings.

More on BIO-TECHNE

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .